Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
about
Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cellsTargeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI InhibitorsVEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideTumors: wounds that do not heal-reduxCombinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusMetabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityMo polyoxometalate nanoparticles inhibit tumor growth and vascular endothelial growth factor induced angiogenesisHigh-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in miceRegorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patientsIdentification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.LPA receptor signaling: pharmacology, physiology, and pathophysiology.Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signalingMolecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.Microparticles mediated cross-talk between tumoral and endothelial cells promote the constitution of a pro-metastatic vascular niche through Arf6 up regulation.TM4SF1: a new vascular therapeutic target in cancerProtein kinase LKB1 promotes RAB7-mediated neuropilin-1 degradation to inhibit angiogenesis.Generation and characterization of a human nanobody against VEGFR-2.Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation.Innovations in studying in vivo cell behavior and pharmacology in complex tissues--microvascular endothelial cells in the spotlight.In vitro evaluation of optimized liposomes for delivery of small interfering RNA.Mechanism of alternative splicing and its regulationTargeted therapies for advanced Ewing sarcoma family of tumors.Nanoparticles for inhibition of in vitro tumour angiogenesis: synergistic actions of ligand function and laser irradiation.Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.Gγ recruitment systems specifically select PPI and affinity-enhanced candidate proteins that interact with membrane protein targetsThe challenge of targeting metastasis.Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targetsCellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Mitotic spindle (DIS)orientation and DISease: cause or consequence?Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma.
P2860
Q24312922-38470990-753C-4995-AEA7-2D736193E79EQ26764892-95DBF5A3-131B-48A1-BD78-F9980F668105Q26770678-984E42BB-E875-4116-8AF3-C770AC43E97CQ26853439-2F3E99CD-E395-4EC7-AB8D-5F9824C7447BQ27001560-B804A263-C9D7-4D71-A688-97D5A224C917Q27025007-F62136FC-53FD-4475-8A11-7BE126C774B1Q28822397-794224BB-26F8-481F-A547-1D264080F1E0Q30365660-4D48980E-01EE-49AF-97E9-0C065FE69AC7Q30399006-DEEADC42-F692-4236-A5F5-B2357183918EQ30446280-EC3C8BB0-105A-41B8-9A24-11CC75C3D6FEQ30593460-CAAFC7D5-58DB-4486-848C-42ACEA9EC7CDQ33576750-C25D3741-D41B-40FF-B3C5-14AD6A8678FBQ33645711-505F4D49-275C-49D9-818E-4625D611111CQ33770680-6079DFE1-496B-4ACA-8D7E-46E77C991E5EQ33825153-EAC64084-9A39-4B2D-89E1-24D5D88848CCQ33828636-4680ADCA-1CD5-4B83-AF93-B4E0CE2F51A6Q33865519-562B8D66-84C2-413A-9F34-C341B0966F49Q33957962-8F364C31-65FF-4835-90DD-D5C231B00379Q34101045-3F7CFDB2-9B52-4D51-AE7C-5076EA268166Q34115934-A378D6BA-23B6-45AD-BA43-41104E22D11BQ34254434-2E1D2DB1-4856-46FC-AC0D-C1AA77798839Q34311557-8C162B96-A335-4266-8501-FF93803BFD85Q34523277-D3E4945D-82AF-4F87-A60D-42B7EA48D86FQ34723329-4A8E1781-759B-4125-858F-7723AF27843AQ35000486-906C906F-9C4F-4704-B703-E218AAE7B8ACQ35140847-5D83ABFB-48F2-4DAF-BE8A-CE9A4B2264BAQ35179872-1F775BD4-0847-4158-84CB-2B3EAF9DBA64Q35589492-D5ADBC98-970C-4F3A-96AD-B981F63D1DABQ35723548-20D3803B-85C7-488C-B6A6-77C1F590826BQ36067203-08EFB0FF-BD41-4463-923C-41DD449D5DE1Q36076814-D7834A58-B80E-49F1-A1C2-8A3F99D353BEQ36279494-30ADD081-A115-4710-8FC6-784B05798804Q36297830-36B4FBB7-B7FD-4F27-9ACB-19DEF2754F7AQ36322825-17E18071-CE66-43C1-8932-42B6C8FEA347Q36357152-6F08CF53-107B-461C-BE7C-E40DC8D84605Q36378883-D51F8C46-5319-49B8-B5DB-7C118FBF50F0Q36428702-08829F11-709C-42FA-9846-6E66684A2024Q36436763-AA571443-3D57-432C-B8B5-423AB6738628Q36486600-331A5D36-6827-46B4-A712-B7420C2CEE9FQ36502721-6B0009E3-4B07-4C1D-B88C-C483D5FE0D3B
P2860
Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
@ast
Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
@en
type
label
Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
@ast
Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
@en
prefLabel
Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
@ast
Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
@en
P2093
P2860
P1433
P1476
Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
@en
P2093
Basel Sitohy
Harold F Dvorak
Janice A Nagy
P2860
P304
P356
10.1158/0008-5472.CAN-11-3406
P407
P577
2012-04-01T00:00:00Z